NovaBridge Biosciences (NBP) Operating Expenses (2019 - 2025)

NovaBridge Biosciences (NBP) has 5 years of Operating Expenses data on file, last reported at -$72.9 million in Q4 2025.

• Quarterly Operating Expenses fell 445.21% year-over-year to -$72.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$94.3 million (down 83.31% YoY) and the FY2025 annual result came in at -$94.3 million, down 83.31% from the prior year.
• Operating Expenses declined to -$72.9 million in Q4 2025 per NBP's latest filing, from -$9.0 million in the prior quarter.
• Across five years, Operating Expenses topped out at $82.8 million in Q4 2023 and bottomed at -$72.9 million in Q4 2025.
• The 3-year median for Operating Expenses is -$10.0 million (2023), against an average of -$7.4 million.
• Peak annual rise in Operating Expenses reached 58.49% in 2025, while the deepest fall reached 445.21% in 2025.
• Tracing NBP's Operating Expenses over 3 years: stood at $82.8 million in 2023, then plunged by 116.15% to -$13.4 million in 2024, then sank by 445.21% to -$72.9 million in 2025.
• Per Business Quant, the three latest NBP Operating Expenses figures stand at -$72.9 million (Q4 2025), -$9.0 million (Q3 2025), and -$7.1 million (Q2 2025).

Peer Comparison